by Rod Raynovich | Mar 5, 2010 | BIOgraph
The rally in biotech is back with lots of help from InterMune (ITMN).The stock was up over 60% to 23 this am after the Company posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee(PADAC) meeting to review the NDA for pirfenidone...
by Rod Raynovich | Mar 4, 2010 | BIOgraph
Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama: Robert Langreth writing in Forbes offers the potential of...
by Rod Raynovich | Mar 3, 2010 | BIOgraph
Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint...
by Rod Raynovich | Feb 17, 2010 | BIOgraph
The drive to reduce healthcare costs and perform Comparative Effectiveness Research can get support from next generation diagnostic tests. A recent article by Bill Malone in Clinical Laboratory News, February 2010 Vol.36 No.2, presents an optimistic scenario for the...
by Rod Raynovich | Feb 15, 2010 | BIOgraph
Complete Genomics 2/18/10 Molecular Diagnostics and Genomics “Powering large-scale human genome studies”. Private Company Summary Complete Genomics(CGI) provides high quality, affordable DNA sequencing for commercial- scale research of the...
by Rod Raynovich | Feb 10, 2010 | BIOgraph
Clinical Profile concerns spur a big sell-off : ISIS shares down 14.6% to $9.40 on volume of 10.6M shares The Mipomersen Phase 3 study in patients with Heterozygous Familial Hypochesterolemia, a genetic disorder, met its primary endpoint but investors were worried...
by Rod Raynovich | Feb 9, 2010 | BIOgraph
Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development and commercialization of genomic-based clinical laboratory services for...
by Rod Raynovich | Feb 5, 2010 | BIOgraph
Microfluidics (MFLU.OB-$0.90) -a leader in advanced, nano-material, processing for a variety of industries A turn-around play with value characteristics This is a “heads-up” on a special report that we will issue post-earnings within two weeks on the...
by Rod Raynovich | Jan 29, 2010 | BIOgraph
In a volatile sell-off day involving tech stocks, the biotech world was relatively calm. Despite good news on corporate earnings and a GDP with an annual 5.7% annual growth, investors chose to take profits even on solid player like Microsoft down over 3% today. Market...
by Rod Raynovich | Jan 28, 2010 | BIOgraph
Large Cap biomedical stocks held firm on another volatile but down day in the market driven by a host of macro and fundamental factors: earnings, Davos, Greece,China, politics, Bernanke confirmation, strong dollar, jobs, etc. In this convoluted market the technology...
